Alnylam Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an additional 1,125,000 shares at a public offering price of $10.75 per share. As a result, the company will issue a total of 8,625,000 shares in the offering and will receive aggregate net proceeds, after underwriting discounts and commissions

Feed Date: 
February 15, 2012